Use

The U.S. FDA approved eribulin mesylate (also referred to as E7389) in November 2010 for the treatment of metastatic breast cancer (MBC) for patients who previously received at least two chemotherapeutic regimens for late-stage disease. Eribulin is a synthetic analog of the marine natural product halichondrin B, which is isolated from the sea sponge Halichondria okadai. Eribulin retains most of the structural elements that constitute the right hand side of halichondrin B; structure–activity relationship (SAR) studies suggested that the antitumor activity of halichondrin B resides in that part of the molecule . Eribulin is a microtubule inhibitor that binds close to the vinca-binding site of tubulin. Unlike most tubulin inhibitors like taxanes, epothilones, and vinca alkaloids that inhibit microtubule dynamic instability by changing tubulin addition and loss parameters, eribulin’s effects on dynamic instability are novel in that eribulin inhibits the growth phase of microtubules without affecting the shortening phase by binding to microtubule plus ends.

Eribulin manufacturers

• Eribulin
• 
• US $1.00 / g
• 2024-10-22
• CAS:441015-17-6
• Min. Order: 1g
• Purity: 85.0-99.8%
• Supply Ability: 20tons

• Eribulin
• 
• US $0.00-0.00 / G
• 2022-05-11
• CAS:253128-41-5
• Min. Order: 1G
• Purity: 99%HPLC
• Supply Ability: 100KG

• Eribulin
• 
• US $12.00 / g
• 2021-11-27
• CAS:253128-41-5
• Min. Order: 1KG
• Purity: 99%
• Supply Ability: 5ton/Month